Alan H. Fairlamb

Alliance T.B.

Altcheh J.

Andrade H.M.

Andrade S.G.

Andrews K.T.

Ang C.W.

Araldi R.P.

Aubé J.

Bahia M.T.

Balasubramanian B.

Barreto-Bergter E.

Berriman M.

Bisser S.

Blumenstiel K.

Boiani M.

Brener Z.

Bruhn D.F.

Bustamante J.M.

Campos M.C.

Chung M.C.

Collins A.R.

Darsaud A.

de Andrade A.L.

Deavall D.G.

Dikhit M.R.

Docampo R.

Dodd M.C.

Dogra M.

El-Sayed N.M.

Enanga B.

Eperon G.

Fabbro D.L.

Fairlamb A.H.

Fernández M.L.

Ferreira R.C.

Filardi L.S.

Fonseca-Berzal C.

Garavaglia P.A.

Goijman S.G.

Gupta S.

Gurumurthy M.

Hall B.S.

Hayashi M.

Henderson G.B.

Henriques C.

Ivens A.C.

Jacobs R.T.

Janssens P.G.

Jeganathan S.

Jennings F.W.

Kaiser M.

Kubata B.K.

Lewis M.D.

Likeufack A.C.L.

Maina N.

Makarov V.

Marin-Neto J.A.

Matsumoto M.

Maya J.D.

Mejia A.M.

Mejía-Jaramillo A.M.

Mesu V.K.B.K.

Miura K.

Moens F.

Molina I.

Moreno M.

Moreno S.N.J.

Morillo C.A.

Mortelmans K.

Mukherjee T.

Mukkavilli R.

Murta S.M.

Murta S.M.F.

Neal R.A.

Nesslany F.

Nogoceke E.

Nogueira F.B.

Olmo F.

Panicucci R.

Papadopoulou M.V.

Patterson S.

Interest in nitroheterocyclic drugs for the treatment of infectious diseases has undergone a resurgence in recent years. Here we review the current status of monocyclic and bicyclic nitroheterocyclic compounds as existing or potential new treatments for visceral leishmaniasis, Chagas' disease and human African trypanosomiasis. Both monocyclic (nifurtimox, benznidazole and fexinidazole) and bicyclic (pretomanid (PA-824) and delamanid (OPC-67683)) nitro-compounds are prodrugs, requiring enzymatic activation to exert their parasite toxicity. Current understanding of the nitroreductases involved in activation and possible mechanisms by which parasites develop resistance is discussed along with a description of the pharmacokinetic / pharmacodynamic behaviour and chemical structure-activity relationships of drugs and experimental compounds.</p

Fairlamb, Alan H.

Patterson, Stephen

University of Dundee Online Publications

Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis

English

Interest in nitroheterocyclic drugs for the treatment of infectious diseases has undergone a resurgence in recent years. Here we review the current status of monocyclic and bicyclic nitroheterocyclic compounds as existing or potential new treatments for visceral leishmaniasis, Chagas’ disease and human African trypanosomiasis. Both monocyclic (nifurtimox, benznidazole and fexinidazole) and bicyclic (pretomanid (PA-824) and delamanid (OPC-67683)) nitro-compounds are prodrugs, requiring enzymatic activation to exert their parasite toxicity. Current understanding of the nitroreductases involved in activation and possible mechanisms by which parasites develop resistance is discussed along with a description of the pharmacokinetic / pharmacodynamic behaviour and chemical structure-activity relationships of drugs and experimental compounds.</jats:sec

Stephen Patterson

Crossref

Current Medicinal Chemistry

https://discovery.dundee.ac.uk/ws/files/21438473/Author_accepted_version.pdf

Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis

Abstract

Similar works

Full text

Available Versions

University of Dundee Online Publications

University of Dundee Online Publications

Crossref